Neuropace IncFDA approval for AI-driven ECoG Assistant, a new product feature.

NeuroPace received U.S. Food and Drug Administration approval for ECoG Assistant, the first AI-driven clinician-enabled feature designed to aid epilepsy care using long-term intracranial EEG data. Built on 124,450 epileptologist-labeled records, the tool identifies ECoGs of Interest and allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions. Chief Medical Officer Martha Morrell said the feature represents an important advancement, with faster access to insights for more informed care. CEO Joel Becker added that the approval shows how the firm's data advantage is moving toward practical tools for clinicians. The company debuted the technology at the ASSFN Annual Meeting on May 30 and has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026.
Neuropace IncFDA approval for AI-driven ECoG Assistant, a new product feature.